NASDAQ

Updated Oct 30, 3:14 PM ET

OABI

OmniAb, Inc.
$4.94CS band Balanced

−$0.29 (5.64%) Today

Oct 30, 3:14 PM ET

About OABI

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

News

2 latest

Zacks Investment Research

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates

OmniAb, Inc. (OABI) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $3.99 million exceeding expectations by 10.12%. The company has outperformed the S&P 500 by 182.7% year-to-date.

UTHR

Zacks Investment Research

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.

Headlines open the publisher's site.